ODAC to discuss pazopanib, ridaforolimus

FDA's Oncologic Drugs Advisory Committee will meet on March 20 to discuss applications for two sarcoma drugs -- Votrient pazopanib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Taltorvic ridaforolimus from Merck & Co. Inc. (NYSE:MRK). Votrient is under review for patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. GSK submitted the sNDA for Votrient in July. A 10-month standard review would place the PDUFA date around May; an exact date is not disclosed. Votrient, a broad spectrum inhibitor of VEGF and other tyrosine kinases, is already approved in the U.S. to treat advanced renal cell carcinoma (RCC). ...